ACB $12.020 (2.12%)

ACNNF $0.100 (-2.44%)

AERO $3.555 (0%)

AGEEF $0.080 (4.87%)

ALEAF $0.380 (7.86%)

AMMJ $0.131 (-13.25%)

APHA $4.300 (2.63%)

ARNA $65.920 (0.26%)

ATT:CNX $0.080 (0%)

ATTBF $0.008 (0%)

AUSA:CNX $0.180 (-5.26%)

AUSAF $0.137 (-7.24%)

AVXL $4.710 (-1.46%)

BAMM:CNX $0.390 (-2.5%)

BBM:CNX $0.050 (11.11%)

BBRRF $0.039 (4.24%)

BE:CNX $0.005 (0%)

BIO:CNX $0.070 (0%)

BLEVF $0.003 (141.67%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.530 (9.28%)

BLOZF $0.395 (9.72%)

BUDZ $0.280 (3.67%)

BXNG $0.600 (-4.76%)

CADMF $0.660 (8.2%)

CALI:CNX $0.100 (11.11%)

CANN $0.415 (-0.18%)

CARA $17.630 (-0.06%)

CBII:CNX $0.095 (-5%)

CBIIF $0.078 (4%)

CBWTF $0.220 (7.17%)

CGC $17.420 (8.74%)

CGRW $0.090 (-10.89%)

CHOO:CNX $0.110 (-8.33%)

CHOOF $0.089 (3.5%)

CNBX $0.221 (0.71%)

CNGGF $0.634 (0%)

CODI $16.510 (2.55%)

CPMD $1.110 (0.91%)

CRBP $7.680 (-0.26%)

CRON $6.320 (4.98%)

CROP:CNX $0.015 (0%)

CRTPF $1.682 (-0.77%)

CRXPF $0.030 (81.82%)

CSI:CNX $0.910 (10.98%)

CURR $1.830 (-1.08%)

CVSI $0.610 (8.91%)

DIGP $0.039 (5.35%)

DXBRF $0.140 (0%)

EAPH $0.001 (0%)

EAT:CNX $0.025 (0%)

EEVVF $0.047 (4.06%)

EMHTF $0.130 (3.01%)

EPWCF $0.043 (-7.53%)

EVIO $0.019 (-2.06%)

FFRMF $0.028 (-9.27%)

FFT:CNX $0.040 (14.29%)

FNNZF $0.077 (-1.03%)

GGTTF $0.106 (-3.21%)

GLDFF $0.014 (-4.44%)

GLH:CNX $0.020 (33.33%)

GNBT $0.620 (0%)

GRIN:CNX $0.135 (8%)

GRWG $6.620 (-1.34%)

GSTR:CNX $0.065 (0%)

GTBIF $11.290 (9.66%)

GTII:CNX $15.390 (10.01%)

GWPH $127.900 (-0.16%)

HEXO $0.750 (1.99%)

HHPHF $0.008 (0%)

HLSPY $0.510 (0%)

HMLSF $5.117 (2.75%)

HMPPF $0.498 (0%)

HRVOF $0.060 (11.11%)

HSTRF $0.070 (-8.96%)

HUGE:CNX $5.130 (-2.29%)

IAN:CNX $0.305 (0%)

IGC $0.577 (1.82%)

IGXT $0.211 (4.41%)

IIPR $90.780 (1.15%)

IMLFF $5.130 (5.49%)

INQD $0.003 (-1.67%)

IONC:CNX $0.015 (0%)

IONKF $0.015 (0%)

ISOL:CNX $0.065 (8.33%)

ISOLF $0.045 (-4.19%)

ITHUF $0.185 (0.65%)

IVITF $0.023 (4.55%)

JWCAF $0.009 (56.52%)

KALTF $0.015 (0%)

KBEV:CNX $0.080 (14.29%)

KBEVF $0.056 (6.73%)

KHRNF $0.385 (-0.31%)

KSHB $0.740 (-3.9%)

LHS:CNX $0.495 (13.79%)

LHSIF $0.364 (15.52%)

LOVE:CNX $0.110 (0%)

LXRP $0.247 (-1.4%)

LXX:CNX $0.335 (1.52%)

MCIG $0.028 (0%)

MEDIF $0.856 (4.39%)

MGWFF $0.060 (-7.69%)

MICWF $0.101 (7.45%)

MJ:CNX $0.040 (0%)

MJNA $0.016 (2.5%)

MNTR $0.095 (5.56%)

MRRCF $0.003 (-2.86%)

MWM:CNX $0.130 (13.04%)

MYM:CNX $0.070 (0%)

MYMMF $0.052 (3%)

NCNNF $0.152 (21.52%)

NDVAF $0.207 (-1%)

NGW:CNX $0.155 (-3.13%)

NRXCF $0.071 (-9.03%)

NSPDF $0.039 (-0.11%)

NTEC $0.290 (5.42%)

NVTQF $0.140 (0%)

NWKRF $0.424 (0%)

NXGWF $0.120 (0.76%)

NXTTF $0.265 (0.68%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

OWCP $0.010 (-1.89%)

PHCG $0.360 (2.86%)

PHVAF $0.059 (6.31%)

PILL:CNX $0.800 (2.56%)

PKG:CNX $0.095 (-5%)

PLPRF $0.434 (-2.45%)

PLUS:CNX $0.570 (-5%)

PMCB $0.023 (-3.85%)

PNPL $0.120 (0%)

POTN $0.014 (5.81%)

PRCNF $0.010 (81.82%)

PTNYF $0.070 (-8.19%)

QCA:CNX $0.105 (0%)

RDDTF $0.107 (-2.73%)

RLLVF $0.025 (-10.71%)

RMHB $0.031 (-4.69%)

RQB:CNX $0.005 (0%)

RQHTF $0.198 (23.26%)

RVVQF $0.013 (0%)

SLNG:CNX $0.160 (-3.03%)

SMG $139.070 (0.98%)

SNN:CNX $0.155 (0%)

SNNVF $0.115 (15%)

SOL:CNX $0.490 (8.89%)

SOLCF $0.360 (7.95%)

SPLIF $0.020 (-15.25%)

SPRWF $0.172 (0.71%)

SRNA $0.028 (-0.62%)

STEM:CNX $0.560 (-1.75%)

STMH $0.440 (-2.22%)

SUN:CNX $0.170 (6.25%)

TBPMF $0.152 (-1.81%)

TCAN:CNX $1.020 (2%)

TCNAF $0.700 (0%)

TER:CNX $3.360 (7.35%)

TGEN $0.725 (2.11%)

TGIF:CNX $0.065 (-7.14%)

TGIFF $0.050 (-7.41%)

THC:CNX $0.165 (-2.94%)

THCBF $0.118 (-9.92%)

TLRY $8.010 (8.1%)

TOKI:CNX $0.030 (0%)

TRLFF $0.034 (-3.14%)

TRSSF $2.490 (8.26%)

TRTC $0.104 (5.43%)

TURV $0.080 (1.91%)

VBIO $0.095 (53.23%)

VIDA:CNX $0.065 (-7.14%)

VIN:CNX $0.025 (0%)

VPRB $0.023 (0.22%)

VRNDF $0.400 (2.3%)

VRT:CNX $0.170 (0%)

VRTHF $0.107 (0%)

VVCIF $0.174 (1.4%)

WAYL:CNX $0.740 (0%)

WDDMF $0.350 (2.79%)

WLDFF $0.125 (8.41%)

XXII $0.756 (-2.57%)

ZDPY $0.131 (0%)

ZYNE $3.730 (8.43%)

Technical420 Site Search

Returned 16 result(s).

CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has launched the medical cannabis industry’s first interactive dashboard which gives any industry stakeholders access to key patient insights derived from the Company’s…

CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors. Effective immediately, Mr. Brogan will…

CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it has partnered with Licensed Producer, Vireo Health International Inc. (“Vireo”) (CNSX: VREO, OTCQX: VREOF), to advance the proof of safety…

CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today released its CEO’s 2019 Year In Review.  The letter, which has also been sent to Investors, provides an update on the growth…

CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced that it is partnering with Licensed Producer FCM Global (“FCM”), the first Colombian cannabis company to be fully licensed in research, cultivation,…

CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced its results for the three and nine months ended September 30, 2019. All figures are reported in Canadian dollars ($), unless otherwise…

CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights (CSE:CBII; OTCQB: CBIIF), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced preliminary unaudited revenue of approximately $4.2 million1  for the three months ended September 30, 2019, representing a 29% growth from the previous quarter. The company also…

CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing Real-World Evidence driven from the point-of-care to the medical cannabis community, announced today that it has been selected as exclusive research technology platform for the leading, and only, independent scientific body on drugs in the…

CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations

CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has successfully completed Phase One of its Clinical Decision Support (CDS) tool integration including targeted user testing with its partner Premier Health Group…

CB2 Insights Is Making It Easier For Physicians To Prescribe Medical Cannabis

Although many investors have been focused on the plant-touching businesses when it comes to the cannabis industry, we believe that there is a significant opportunity for ancillary cannabis businesses. In the 1800s, thousands of miners and entrepreneurs traveled to California in hopes of finding gold. Most of these people were…

Older Posts »

Search Again